Concepts (102)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Renal Cell | 11 | 2023 | 3143 | 1.340 |
Why?
|
Kidney Neoplasms | 11 | 2023 | 4262 | 1.200 |
Why?
|
Quarantine | 1 | 2021 | 170 | 0.650 |
Why?
|
Nephrectomy | 2 | 2021 | 1050 | 0.580 |
Why?
|
Drug Repositioning | 1 | 2019 | 230 | 0.570 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2019 | 664 | 0.540 |
Why?
|
Infection Control | 1 | 2021 | 965 | 0.450 |
Why?
|
Blood Pressure Determination | 1 | 2015 | 633 | 0.380 |
Why?
|
Antihypertensive Agents | 1 | 2015 | 2047 | 0.260 |
Why?
|
Hypertension | 2 | 2015 | 8479 | 0.250 |
Why?
|
Protein Kinase Inhibitors | 2 | 2023 | 5534 | 0.240 |
Why?
|
Overweight | 1 | 2015 | 2371 | 0.240 |
Why?
|
Vascular Endothelial Growth Factor A | 4 | 2023 | 3511 | 0.210 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2021 | 3480 | 0.200 |
Why?
|
Neoplasms | 5 | 2021 | 21696 | 0.190 |
Why?
|
Prostatic Neoplasms | 2 | 2021 | 11126 | 0.180 |
Why?
|
Disease-Free Survival | 2 | 2021 | 6896 | 0.170 |
Why?
|
Blood Pressure | 1 | 2015 | 8551 | 0.170 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2021 | 841 | 0.170 |
Why?
|
Chemokine CXCL10 | 1 | 2019 | 305 | 0.160 |
Why?
|
Cisplatin | 1 | 2024 | 1662 | 0.150 |
Why?
|
Body Mass Index | 1 | 2015 | 12721 | 0.150 |
Why?
|
Drug Approval | 1 | 2021 | 742 | 0.120 |
Why?
|
Databases, Genetic | 1 | 2021 | 1783 | 0.120 |
Why?
|
Androgen Antagonists | 1 | 2021 | 1377 | 0.110 |
Why?
|
Systole | 1 | 2015 | 958 | 0.110 |
Why?
|
Acute Kidney Injury | 1 | 2024 | 1968 | 0.100 |
Why?
|
Prognosis | 3 | 2021 | 29060 | 0.100 |
Why?
|
Immunotherapy | 3 | 2023 | 4446 | 0.100 |
Why?
|
Pyrimethamine | 1 | 2010 | 97 | 0.090 |
Why?
|
Humans | 23 | 2024 | 744366 | 0.090 |
Why?
|
Tetrahydrofolate Dehydrogenase | 1 | 2010 | 143 | 0.090 |
Why?
|
Drug Therapy, Combination | 1 | 2020 | 6489 | 0.090 |
Why?
|
Genetic Fitness | 1 | 2010 | 121 | 0.080 |
Why?
|
Patient Selection | 1 | 2021 | 4216 | 0.080 |
Why?
|
Electronic Health Records | 2 | 2023 | 4468 | 0.080 |
Why?
|
Artificial Intelligence | 1 | 2021 | 2213 | 0.080 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2021 | 4479 | 0.070 |
Why?
|
Cohort Studies | 5 | 2024 | 40559 | 0.070 |
Why?
|
Comorbidity | 1 | 2021 | 10388 | 0.070 |
Why?
|
Time Factors | 2 | 2021 | 40075 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2019 | 9955 | 0.070 |
Why?
|
Risk Factors | 4 | 2024 | 72296 | 0.070 |
Why?
|
Retrospective Studies | 6 | 2024 | 77460 | 0.060 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2021 | 8432 | 0.060 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 5223 | 0.060 |
Why?
|
Male | 8 | 2021 | 350115 | 0.060 |
Why?
|
Genome-Wide Association Study | 1 | 2022 | 12262 | 0.060 |
Why?
|
Emergency Service, Hospital | 1 | 2023 | 7658 | 0.060 |
Why?
|
Antimalarials | 1 | 2010 | 905 | 0.060 |
Why?
|
Natural Language Processing | 2 | 2021 | 1041 | 0.050 |
Why?
|
Aged | 6 | 2023 | 163288 | 0.050 |
Why?
|
Interleukin-7 | 1 | 2022 | 142 | 0.050 |
Why?
|
Mitosis | 1 | 2007 | 1208 | 0.050 |
Why?
|
Tennessee | 1 | 2021 | 117 | 0.050 |
Why?
|
Cell Death | 1 | 2007 | 1707 | 0.050 |
Why?
|
Evolution, Molecular | 1 | 2010 | 1939 | 0.050 |
Why?
|
Chromosome Aberrations | 1 | 2007 | 1813 | 0.050 |
Why?
|
Plasmodium falciparum | 1 | 2010 | 1732 | 0.050 |
Why?
|
Brain Neoplasms | 1 | 2021 | 8861 | 0.050 |
Why?
|
Molecular Sequence Annotation | 1 | 2021 | 528 | 0.040 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 11525 | 0.040 |
Why?
|
Anilides | 1 | 2021 | 408 | 0.040 |
Why?
|
Germ Cells | 1 | 2022 | 631 | 0.040 |
Why?
|
Creatinine | 1 | 2024 | 1919 | 0.040 |
Why?
|
Death | 1 | 2023 | 678 | 0.040 |
Why?
|
Antineoplastic Agents | 1 | 2021 | 13693 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2022 | 13104 | 0.040 |
Why?
|
Middle Aged | 5 | 2024 | 213390 | 0.040 |
Why?
|
Follow-Up Studies | 2 | 2019 | 39052 | 0.040 |
Why?
|
Tumor Burden | 1 | 2022 | 1915 | 0.040 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2023 | 1821 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 1038 | 0.030 |
Why?
|
Female | 5 | 2021 | 380193 | 0.030 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2023 | 2110 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2021 | 1584 | 0.030 |
Why?
|
Genes, Protozoan | 1 | 2010 | 163 | 0.020 |
Why?
|
Pyridines | 1 | 2021 | 2825 | 0.020 |
Why?
|
Adult | 3 | 2024 | 214052 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2021 | 3590 | 0.020 |
Why?
|
HCT116 Cells | 1 | 2007 | 409 | 0.020 |
Why?
|
Aged, 80 and over | 2 | 2021 | 57776 | 0.020 |
Why?
|
Macrophages | 1 | 2021 | 5660 | 0.020 |
Why?
|
Genomics | 1 | 2021 | 5717 | 0.020 |
Why?
|
Survival Rate | 1 | 2019 | 12788 | 0.020 |
Why?
|
Cognition | 1 | 2022 | 6770 | 0.020 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2023 | 9240 | 0.020 |
Why?
|
Point Mutation | 1 | 2010 | 1624 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2023 | 19905 | 0.020 |
Why?
|
Drug Resistance | 1 | 2010 | 1608 | 0.010 |
Why?
|
Genomic Instability | 1 | 2007 | 695 | 0.010 |
Why?
|
Risk Assessment | 1 | 2024 | 23336 | 0.010 |
Why?
|
HeLa Cells | 1 | 2007 | 3130 | 0.010 |
Why?
|
Models, Genetic | 1 | 2010 | 3493 | 0.010 |
Why?
|
Saccharomyces cerevisiae | 1 | 2010 | 2751 | 0.010 |
Why?
|
Alleles | 1 | 2010 | 6933 | 0.010 |
Why?
|
Mutation | 1 | 2022 | 29786 | 0.010 |
Why?
|
Prospective Studies | 1 | 2021 | 53290 | 0.010 |
Why?
|
Young Adult | 1 | 2021 | 56429 | 0.010 |
Why?
|
United States | 1 | 2021 | 69872 | 0.010 |
Why?
|
Adolescent | 1 | 2021 | 85779 | 0.010 |
Why?
|
Phenotype | 1 | 2010 | 16367 | 0.010 |
Why?
|
Concepts
(102)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(66)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_